A Prevalence Analysis Of Eosinophilic Bronchitis In Shanghai And Clinical Study Of Treatment With Montelukast

Objective:1. To explored the incidence and clinical feature of EB in Shanghai. 2. To evaluate the efficiency and safety of montelukast in the treatment of EB.Method: A total of 365 patients with chronic cough (lasting>8weeks) or subacute cough ( lasting > 3 weeks ) were recruited from the outpatient clinic of Shanghai First People's Hospital, Tongji Hospital and Putuo District People's Hospital between May 2007 to February 2008. Made diagnoses of EB according to diagnostic criteria published by Chinese Medical Association. Reviewed clinical data of the cases of EB and divided them into three groups in random. Treated the A group with montelukast, B group with budesonide, C group with montelukast and Budesonide, lasting for 4 weeks. Compared the efficiency and safety of the three groups. Result: 1. prevalence rate: EB(3.5%)were defined in 86 subacute cough patients; 30 EB(10.8%)were defined in 279 chronic cough patients; A total of 33EB (9.0%)were defined in 365 subacute or chronic cough patients. 2. Clinical manifestation: persistent chronic cough or recurrent attacks is main manifestation, nonproductive cough (17cases), complicated with slight productive cough(14cases). EB group sputum eosinophil count is obviously higher than control group (30 chronic cough patients without EB as control group) (P<0.01). While there is no statistical significance between the two groups peripheral blood eosinophil count (P>0.05). 3. All the three groups improved the sputum eosinophilia, cough Severity, there is no statistical significance among the three groups efficiency (P<0.01). The sputum eosinophil count and ECP level after treating were obviously decreased in all three groups (P<0.01). 4. No adverse effect of montelukast was observed in this trial.Conclusion: EB is an important cause for chronic cough in Shanghai area. montelukast single or union budesonide can both relieve the cough of EB and it is beneficial for eliminating eosinophilic airway inflammation. the adverse effect of montelukast is few.